WO2009025847A3 - Methods for diagnosis, prognosis and methods of treatment - Google Patents

Methods for diagnosis, prognosis and methods of treatment Download PDF

Info

Publication number
WO2009025847A3
WO2009025847A3 PCT/US2008/009975 US2008009975W WO2009025847A3 WO 2009025847 A3 WO2009025847 A3 WO 2009025847A3 US 2008009975 W US2008009975 W US 2008009975W WO 2009025847 A3 WO2009025847 A3 WO 2009025847A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
methods
prognosis
diagnosis
status
Prior art date
Application number
PCT/US2008/009975
Other languages
French (fr)
Other versions
WO2009025847A2 (en
Inventor
Wendy J Fantl
Santosh K Putta
Omar D Perez
Helen L Francis-Lang
Aileen C Cohen
Original Assignee
Nodality Inc
Wendy J Fantl
Santosh K Putta
Omar D Perez
Helen L Francis-Lang
Aileen C Cohen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nodality Inc, Wendy J Fantl, Santosh K Putta, Omar D Perez, Helen L Francis-Lang, Aileen C Cohen filed Critical Nodality Inc
Priority to JP2010521884A priority Critical patent/JP2010536371A/en
Priority to EP08795509A priority patent/EP2179037A4/en
Priority to AU2008289442A priority patent/AU2008289442A1/en
Priority to CN200880107737A priority patent/CN101802182A/en
Priority to CA2696402A priority patent/CA2696402A1/en
Publication of WO2009025847A2 publication Critical patent/WO2009025847A2/en
Publication of WO2009025847A3 publication Critical patent/WO2009025847A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. The physiological status of a cell can be determined by comparing the intracellular status of one or more activation elements (e.g. the phosphorylation status of a signaling molecule) in a cell (e.g. a cancer cell) to that of another cell (e.g. a normal cell). The physiological status of a cell can be further classified by adding one or more modulators (e.g. an inhibitor or activator) to the cell in question. In some embodiments, the invention is directed to methods of determining a phenotypic profile of a population of cells.
PCT/US2008/009975 2007-08-21 2008-08-21 Methods for diagnosis, prognosis and methods of treatment WO2009025847A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2010521884A JP2010536371A (en) 2007-08-21 2008-08-21 Diagnostic, prognostic and therapeutic methods
EP08795509A EP2179037A4 (en) 2007-08-21 2008-08-21 Methods for diagnosis, prognosis and methods of treatment
AU2008289442A AU2008289442A1 (en) 2007-08-21 2008-08-21 Methods for diagnosis, prognosis and methods of treatment
CN200880107737A CN101802182A (en) 2007-08-21 2008-08-21 Be used to diagnose, the method for prognosis and methods of treatment
CA2696402A CA2696402A1 (en) 2007-08-21 2008-08-21 Methods for diagnosis, prognosis and methods of treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95716007P 2007-08-21 2007-08-21
US60/957,160 2007-08-21
US4892008P 2008-04-29 2008-04-29
US61/048,920 2008-04-29

Publications (2)

Publication Number Publication Date
WO2009025847A2 WO2009025847A2 (en) 2009-02-26
WO2009025847A3 true WO2009025847A3 (en) 2009-06-11

Family

ID=40378879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009975 WO2009025847A2 (en) 2007-08-21 2008-08-21 Methods for diagnosis, prognosis and methods of treatment

Country Status (7)

Country Link
US (3) US20090098594A1 (en)
EP (2) EP2860247A1 (en)
JP (1) JP2010536371A (en)
CN (1) CN101802182A (en)
AU (1) AU2008289442A1 (en)
CA (1) CA2696402A1 (en)
WO (1) WO2009025847A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8273544B2 (en) 2008-07-10 2012-09-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8309306B2 (en) 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
US8815527B2 (en) 2001-07-10 2014-08-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US8865420B2 (en) 2004-07-21 2014-10-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US9034257B2 (en) 2008-10-27 2015-05-19 Nodality, Inc. High throughput flow cytometry system and method
US9115384B2 (en) 2001-07-10 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US9182385B2 (en) 2007-08-21 2015-11-10 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009923A1 (en) * 2005-01-24 2007-01-11 Massachusetts Institute Of Technology Use of bayesian networks for modeling cell signaling systems
WO2007117423A2 (en) 2006-03-31 2007-10-18 Cira Discovery Sciences, Inc. Method and apparatus for representing multidimensional data
AU2008308686B2 (en) * 2007-10-02 2015-01-22 Labrador Diagnostics Llc Modular point-of-care devices and uses thereof
EP2235537A2 (en) * 2008-01-25 2010-10-06 Bristol-Myers Squibb Pharma Company Identification of predictive markers of response to dasatinib in human colon cancer
EP2244738B1 (en) * 2008-01-25 2020-03-04 Gavish-Galilee Bio Applications Ltd Targeting of innate immune response to tumour site
WO2009134944A2 (en) * 2008-04-29 2009-11-05 Nodality, Inc. Methods of determining the health status of an individual
WO2010027002A1 (en) * 2008-09-05 2010-03-11 塩野義製薬株式会社 Ring-fused morpholine derivative having pi3k-inhibiting activity
US20100099109A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc., A Delaware Corporation Methods for Analyzing Drug Response
US20100209929A1 (en) * 2009-01-14 2010-08-19 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of jak/stat activity
US20100204973A1 (en) * 2009-01-15 2010-08-12 Nodality, Inc., A Delaware Corporation Methods For Diagnosis, Prognosis And Treatment
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
US8242248B2 (en) 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
US8187885B2 (en) * 2009-05-07 2012-05-29 Nodality, Inc. Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
US20100297676A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
SG177763A1 (en) * 2009-07-28 2012-03-29 Hoffmann La Roche Non-invasive in vivo optical imaging method
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
EP2476053A4 (en) * 2009-09-08 2014-03-12 Nodality Inc Analysis of cell networks
DK2491385T3 (en) * 2009-10-20 2017-08-28 Diatech Holdings Inc PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS
GB2474777A (en) * 2009-10-22 2011-04-27 Nodality Inc Methods for diagnosis, prognosis, and of determining the treatment for acute leukaemia
AU2011242990B2 (en) * 2010-04-19 2015-02-12 Biomarker Strategies, Llc. Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
US20110318769A1 (en) * 2010-06-24 2011-12-29 National Tsing Hua University Method and composition for targeting vicious cycles of stresses and inflammatory responses
ES2549752T3 (en) * 2010-07-19 2015-11-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and systems for the analysis of individual cells
US20120040361A1 (en) * 2010-07-22 2012-02-16 National Tsing Hua University Methods and compositions for detection of lethal system and uses thereof
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102486474B (en) * 2010-12-06 2014-05-28 北京大学人民医院 Protein chip for chronic hepatitis C outcome prediction in chronic hepatitis C interferon treatment
AR085087A1 (en) 2011-01-21 2013-09-11 Theranos Inc SYSTEMS AND METHODS TO MAXIMIZE THE USE OF SAMPLES
KR20140024914A (en) * 2011-04-29 2014-03-03 셀진 코포레이션 Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US8679760B2 (en) * 2011-05-03 2014-03-25 National Cheng Kung University Biomarker and method for evaluating risk of proliferation, invasion, or metastasis of cancer
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
US20170015975A1 (en) * 2014-02-10 2017-01-19 Nvigen, Inc. Cell modulation nanocomposition, and methods of use
CN104398508B (en) * 2014-11-28 2017-06-13 上海交通大学 Application of the bisindole maleimide derivative in treatment chronic myelocytic leukemia medicine is prepared
US10724071B2 (en) 2015-10-14 2020-07-28 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used
EP3451919A4 (en) * 2016-05-05 2019-12-18 Bestbrain Ltd. Neurofeedback systems and methods
CN107436355A (en) * 2016-05-25 2017-12-05 北京市神经外科研究所 Pass through the kit of protein markers analyte detection endocrine active pituitary adenoma radiation sensitivity
IL266208B1 (en) * 2016-10-23 2024-01-01 Berkeley Lights Inc Methods for Screening B Cell Lymphocytes
US20210041437A1 (en) * 2018-01-23 2021-02-11 Virongy L.L.C. Cofilin phosphorylation for quantifying cd4 t cell damage and predict cd4 t cell recovery from anti-retroviral therapy
CN109260197B (en) * 2018-10-08 2021-02-12 中国医学科学院血液病医院(中国医学科学院血液学研究所) Application of indirubin compound and bortezomib in preparation of medicine for treating multiple myeloma
AR117327A1 (en) 2018-12-20 2021-07-28 23Andme Inc ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM
WO2020154941A1 (en) * 2019-01-30 2020-08-06 Nippon Zoki Pharmaceutical Co., Ltd. Inhibiting or alleviating agent for inflammation in the brain
CN109966284B (en) * 2019-04-22 2021-08-13 上海长征医院 Application of chaetomium globosum lour in preparation of antifungal drug sensitizer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112700A1 (en) * 2001-07-10 2005-05-26 Perez Omar D. Methods and compositions for risk stratification
US20060073474A1 (en) * 2001-07-10 2006-04-06 Perez Omar D Methods and compositions for detecting the activation state of multiple proteins in single cells

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249514A (en) * 1963-11-18 1966-05-03 Bode Harold Eli Production and use of amyloglucosidase
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0327674A3 (en) 1988-02-12 1990-09-05 ING. HERMANN KÜMMERL, LABORGERÄTEBAU, Inh. Ing. Klaus Kümmerl Photographic-processing machine
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US4865708A (en) 1988-11-14 1989-09-12 Vac-Tec Systems, Inc. Magnetron sputtering cathode
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
IE76319B1 (en) 1990-07-23 1997-10-22 Becton Dickinson Co Preservation of cells as controls or standards in cellular analysis
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5264816A (en) * 1991-01-09 1993-11-23 Furnas Electric Company Electrical winding termination structure
WO1992015673A1 (en) 1991-03-11 1992-09-17 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5234816A (en) 1991-07-12 1993-08-10 Becton, Dickinson And Company Method for the classification and monitoring of leukemias
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
EP0610774B1 (en) * 1993-02-09 2001-03-28 Becton, Dickinson and Company Automatic lineage assignment of acute leukemias by flow cytometry
WO1994024314A1 (en) 1993-04-19 1994-10-27 Kauffman Stuart A Random chemistry for the generation of new compounds
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5844979A (en) 1995-02-16 1998-12-01 Global Technologies, Inc. Intelligent switching system for voice and data
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CA2271717A1 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6821740B2 (en) 1998-02-25 2004-11-23 Becton, Dickinson And Company Flow cytometric methods for the concurrent detection of discrete functional conformations of PRB in single cells
US6455263B2 (en) 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
WO1999049019A2 (en) 1998-03-27 1999-09-30 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
WO1999054494A2 (en) 1998-04-17 1999-10-28 Rigel Pharmaceuticals, Inc. Multiparameter facs assays to detect alterations in cellular parameters
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
JP4943585B2 (en) 1999-02-18 2012-05-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Salicylamide-lanthanide complexes for use as luminescent markers
US6506551B1 (en) * 1999-10-08 2003-01-14 North Shore - Long Island Jewish Research Institute CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
WO2001066139A1 (en) * 2000-03-06 2001-09-13 University Of Kentucky Research Foundation Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell
GB0009784D0 (en) * 2000-04-20 2000-06-07 Simeg Limited Methods for clinical diagnosis
WO2002047007A2 (en) * 2000-12-07 2002-06-13 Phase It Intelligent Solutions Ag Expert system for classification and prediction of genetic diseases
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
CA2413475C (en) * 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
US6897954B2 (en) 2002-12-20 2005-05-24 Becton, Dickinson And Company Instrument setup system for a fluorescence analyzer
US7957908B2 (en) 2003-11-17 2011-06-07 New York University System, method and software arrangement utilizing a multi-strip procedure that can be applied to gene characterization using DNA-array data
US7803523B2 (en) * 2004-08-27 2010-09-28 University Health Network Whole blood preparation for cytometric analysis of cell signaling pathways
WO2006050373A2 (en) 2004-11-02 2006-05-11 The Regents Of The University Of California Methods and compositions for modulating apoptosis
US20070009923A1 (en) * 2005-01-24 2007-01-11 Massachusetts Institute Of Technology Use of bayesian networks for modeling cell signaling systems
WO2006086111A2 (en) 2005-02-10 2006-08-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP1857216B1 (en) 2005-03-09 2014-07-30 Senju Metal Industry Co., Ltd. Method of producing particles of low melting point metal and apparatus therefor
WO2007015886A2 (en) 2005-07-21 2007-02-08 Cell Signaling Technology, Inc. Phosphorylated protein markers of gleevec-resistant chronic myelogenous leukemia
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US20070172847A1 (en) * 2005-11-15 2007-07-26 The Regents Of The University Of California Molecular signaling pathways triggered by rituximab: prognostic, diagnostic, and therapeutic uses
NO327906B1 (en) 2006-01-18 2009-10-19 Nexans Cable end shooter
WO2007117423A2 (en) 2006-03-31 2007-10-18 Cira Discovery Sciences, Inc. Method and apparatus for representing multidimensional data
WO2007127335A2 (en) 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
JP2009538436A (en) 2006-05-26 2009-11-05 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム Reversed phase protein arrays, protein activation and expression signatures and related methods
CA2547901A1 (en) * 2006-06-14 2007-12-14 University College Cardiff Consultants Limited Chronic lymphocytic leukaemia
US20100009463A1 (en) 2006-07-13 2010-01-14 Peter Hornbeck Reagents for the detection of protein phosphorylation in signaling pathways
WO2008118823A2 (en) * 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2860247A1 (en) 2007-08-21 2015-04-15 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2009134944A2 (en) * 2008-04-29 2009-11-05 Nodality, Inc. Methods of determining the health status of an individual
US20090269800A1 (en) 2008-04-29 2009-10-29 Todd Covey Device and method for processing cell samples
US20090291458A1 (en) 2008-05-22 2009-11-26 Nodality, Inc. Method for Determining the Status of an Individual
JP2011521168A (en) 2008-05-26 2011-07-21 振明 ▲張▼ Dual rotor engine
US20100030719A1 (en) 2008-07-10 2010-02-04 Covey Todd M Methods and apparatus related to bioinformatics data analysis
US20100014741A1 (en) 2008-07-10 2010-01-21 Banville Steven C Methods and apparatus related to gate boundaries within a data space
GB2474613A (en) 2008-07-10 2011-04-20 Nodality Inc Methods and apparatus related to management of experiments
WO2010006291A1 (en) 2008-07-10 2010-01-14 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
AU2009269054A1 (en) 2008-07-11 2010-01-14 Intellicyt Multi-sample particle analyzer system and method for high throughput screening
US7953708B2 (en) 2008-07-28 2011-05-31 International Business Machines Corporation Optimizing grace period detection for preemptible read-copy update on uniprocessor systems
WO2010028277A1 (en) 2008-09-04 2010-03-11 Beckman Coulter, Inc. Pan-kinase activation and evaluation of signaling pathways
US20100099109A1 (en) 2008-10-17 2010-04-22 Nodality, Inc., A Delaware Corporation Methods for Analyzing Drug Response
US9034257B2 (en) 2008-10-27 2015-05-19 Nodality, Inc. High throughput flow cytometry system and method
US8309306B2 (en) 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
US20100209929A1 (en) 2009-01-14 2010-08-19 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of jak/stat activity
US20100204973A1 (en) 2009-01-15 2010-08-12 Nodality, Inc., A Delaware Corporation Methods For Diagnosis, Prognosis And Treatment
US20100233733A1 (en) 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
US20100215644A1 (en) 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
US8242248B2 (en) 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
US8187885B2 (en) 2009-05-07 2012-05-29 Nodality, Inc. Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
US20100297676A1 (en) 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
EP2476053A4 (en) 2009-09-08 2014-03-12 Nodality Inc Analysis of cell networks
JP2013520208A (en) 2010-02-24 2013-06-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ Diagnosis, prognosis and treatment of autoimmune diseases
WO2011119868A2 (en) 2010-03-24 2011-09-29 Nodality, Inc. Hyper-spatial methods for modeling biological events
US20110262468A1 (en) 2010-04-23 2011-10-27 Nodality, Inc. Method for Monitoring Vaccine Response Using Single Cell Network Profiling
AU2011264714A1 (en) 2010-06-09 2012-12-20 Nodality, Inc. Pathways characterization of cells
US20140017678A1 (en) 2012-06-11 2014-01-16 Nodality, Inc. Pathway characterization of cells
WO2012024546A2 (en) 2010-08-18 2012-02-23 Nodality, Inc. Incorporation of health measurments in analysis and interpretation of functional biological response data
US20140031308A1 (en) 2010-09-08 2014-01-30 Longo Diane Benchmarks for normal cell identification
WO2012083274A2 (en) 2010-12-16 2012-06-21 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20140199273A1 (en) 2011-08-05 2014-07-17 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20130035253A1 (en) 2011-08-05 2013-02-07 Nodality, Inc. A Delaware Corporation Methods for diagnosis, prognosis and methods of treatment
US20130129681A1 (en) 2011-10-04 2013-05-23 Nodality, Inc. Methods for diagnosing solid tumors
US20130123131A1 (en) 2011-11-09 2013-05-16 Nodality, Inc. Process for Ensuring Consistency and Reproducibility of a Diagnostic or Research Method
WO2013112948A1 (en) 2012-01-26 2013-08-01 Nodality, Inc. Benchmarks for normal cell identification
WO2014036040A2 (en) 2012-08-27 2014-03-06 Nodality Inc. Methods for diagnosis, prognosis and methods of treatment
WO2014074646A2 (en) 2012-11-06 2014-05-15 Nodality, Inc. Induced intercellular communication
WO2014081987A1 (en) 2012-11-21 2014-05-30 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2014134570A1 (en) 2013-02-28 2014-09-04 Nodality, Inc. Compositions and methods for autoimmune disease
US20150118247A1 (en) 2013-10-25 2015-04-30 Nodality, Inc. Methods and compositions for immunomodulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112700A1 (en) * 2001-07-10 2005-05-26 Perez Omar D. Methods and compositions for risk stratification
US20060073474A1 (en) * 2001-07-10 2006-04-06 Perez Omar D Methods and compositions for detecting the activation state of multiple proteins in single cells
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2179037A4 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815527B2 (en) 2001-07-10 2014-08-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US9115384B2 (en) 2001-07-10 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US8865420B2 (en) 2004-07-21 2014-10-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US9182385B2 (en) 2007-08-21 2015-11-10 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8273544B2 (en) 2008-07-10 2012-09-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8778620B2 (en) 2008-07-10 2014-07-15 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US9500655B2 (en) 2008-07-10 2016-11-22 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US9034257B2 (en) 2008-10-27 2015-05-19 Nodality, Inc. High throughput flow cytometry system and method
US8309306B2 (en) 2008-11-12 2012-11-13 Nodality, Inc. Detection composition

Also Published As

Publication number Publication date
CN101802182A (en) 2010-08-11
AU2008289442A1 (en) 2009-02-26
US20120309029A1 (en) 2012-12-06
US9182385B2 (en) 2015-11-10
CA2696402A1 (en) 2009-02-26
US20160097770A1 (en) 2016-04-07
EP2179037A4 (en) 2010-12-22
EP2179037A2 (en) 2010-04-28
JP2010536371A (en) 2010-12-02
US20090098594A1 (en) 2009-04-16
EP2860247A1 (en) 2015-04-15
WO2009025847A2 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2009025847A3 (en) Methods for diagnosis, prognosis and methods of treatment
Jain et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
Zhou et al. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients
TW200512298A (en) Method of diagnosing breast cancer
WO2005084109A3 (en) Cancer specific gene mh15
TW200639163A (en) RAF inhibitor compounds and methods
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2007109571A3 (en) Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2007047754A3 (en) Mtor pathway theranostic
WO2008005814A3 (en) Method and apparatus for diagnosing pre-eclampsia
BR112012017084A2 (en) methods for predicting triple-negative breast cancer response to therapy
MX336675B (en) Screening for anti-cancer compounds using netrin-1 activity.
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
Han et al. DNA methylation and hypertension: emerging evidence and challenges
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2522743A3 (en) Genetic variants contributing to risk of prostate cancer
Tippu et al. Evolution of renal cell carcinoma
WO2008017002A3 (en) Polymorphisms in genes affecting cns disorders and uses thereof
MX343801B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer.
MX339427B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer.
AU2018239989A8 (en) Methods of measuring signaling pathway activity for selection of therapeutic agents
MX2013011431A (en) Methods for predicting and improving the survival of gastric cancer patients.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880107737.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795509

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008289442

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2696402

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010521884

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008795509

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008289442

Country of ref document: AU

Date of ref document: 20080821

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1966/DELNP/2010

Country of ref document: IN